A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: "Treating critical limb ischemia like acute coronary syndrome"

Journal of Invasive Cardiology

Volumn 17, Issue 8, 2005, Pages 427-432

  Allie, David E ^a   Hebert, Chris J ^a   Lirtzman, Mitchell D ^a   Wyatt, Charles H ^a   Keller, V Antoine ^a   Khan, Mohamed H ^a   Khan, Muhammad A ^a   Fail, Peter S ^a   Vivekananthan, Krishnamoorthy ^a   Allie, Sonja E ^a   Mitran, Elena V ^a   Chaisson, Gary ^a   Stagg III, Samuel J ^a   Allie, Adam A ^a   McElderry, Michael W ^a   Barker, Esmond A ^a   Walker, Craig M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; THROMBIN INHIBITOR; TIROFIBAN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; THROMBIN; TYROSINE;

ACUTE CORONARY SYNDROME; ANGIOGRAPHY; ANTICOAGULATION; ARTICLE; ARTIFICIAL EMBOLISM; BRAIN HEMORRHAGE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SAFETY; ECHOGRAPHY; FALSE ANEURYSM; FEASIBILITY STUDY; HEMOSTASIS; HUMAN; LIMB ISCHEMIA; LIMB SALVAGE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; RESTENOSIS; RETROPERITONEAL HEMATOMA; STROKE; THROMBOSIS; VASCULAR ACCESS; ACUTE DISEASE; AGED; BLOOD; COMPARATIVE STUDY; DRUG ANTAGONISM; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; ISCHEMIA; LEG; MALE; METABOLISM; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VASCULARIZATION;

ACUTE DISEASE; AGED; ANGIOPLASTY, BALLOON; ANTICOAGULANTS; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HIRUDINS; HUMANS; ISCHEMIA; LEG; MALE; MYOCARDIAL ISCHEMIA; PEPTIDE FRAGMENTS; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THROMBIN; TREATMENT OUTCOME; TYROSINE;

EID: 25144466157     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-1324.
2. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Eng J Med 1992;326:381-386.
3. Becker GJ, McClennt TE, Kovacs ME et al. The importance of increasing public awareness of peripheral artery disease. J Vasc Interv Radiol 2002;13:7-11.
4. Yost, ML. Peripheral arterial disease: A report by the Sage Group. 2004; Vol. II.
5. Anonymous. Second European consensus document on chronic critical limb ischemia. Eur J Vasc Surg 1992;6(Suppl A):1-32.
6. Fisher RK, Harris PL. Epidemiological and economic considerations in the critically ischemic limb. "Critical Limb Ischemia." 1999, pp 19-25.
7. Dormandy JA, Ray S. The natural history of peripheral arterial disease. In: Tooke JE, Loew GD, editors. A Textbook of Vascular Medicine. London: Arnold, 1996: pp. 162-75.
8. Transatlantic Inter-Society Consensus (TASC) on Management of Peripheral Arterial Disease (PAD). J Vasc Surg 2000;31:1-296.
9. Myhre H, Wisto F. What are the costs of critical limb ischemia? Critical Ischemia 1996;5:83-87.
10. Aguirre FV, Gill GB. Increasing benefit, reducing risk: Focusing on hemorrhagic complications in percutaneous coronary intervention. J Invasive Cardiol 2002;14:48B-54B.
11. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrilin in patients undergoing percutaneous coronary intervention. The EPIC Investigators. Circulation 1995;91:2882-2890.
12. Shammas NW. Complications in peripheral vascular interventions: Emerging role of direct thrombin inhibitors. J Vasc Interv Radiol 2005;16:165-171.
13. Lincoff AM, Bittl JA, Harrington RA, et al., for the REPLACE-2 Investigators. Bivalirudin and provisional GP IIb/IIIa blockade compared with heparin and planned GP IIb/IIIa blockade during percutaneous coronary angioplasty. JAMA 2003;289:853-863.
14. Lincoff AM, Kleiman NS, Kattke-Marchant K, et al. Bivalirudin with planned or provisional abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002;143:846-853.
15. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet 1998;352:87-92.
16. The ESPRIT Trial Investigators. Platelet glycoprotein IIb/IIIa integrilin blockade with eptifibatide in coronary stent intervention; The ESPRIT trial: A randomized controlled trial. JAMA 2001;285:2468-2473.
17. Allie DE, Lirtzman MD, Walker CM, et al. Bivalirudin as a foundation anticoagulant in peripheral vascular disease: A safe and feasible alternative for renal and iliac interventions. J Invas Cardiol 2003;15:334-342.
18. Shammas N. An overview of antithrombins in peripheral vascular interventions. J Invasive Cardiol 2004;16:440-443.
19. Allie DE. Patients with peripheral artery disease undergoing percutaneous peripheral interventions are at increased risk for complications without adequate anticoagulation. J Invasive Cardiol 2004;16(Suppl G):18-21.
20. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low molecular weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1998;114:489S-510S.
21. Blankenship JC, Hellkamp AS, Aguirre FV, et al. Vascular access site complications after percutaneous coronary intervention with abciximab in the evaluation of c7E3 for the prevention of ischemic complications (EPIC) Trial. Am J Cardiol 1998;81:36-40.
22. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
23. Kinnard TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003;92:930-935.
24. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004;292:1555-1562.
25. Vainio E, Salenius JP, Lepantalo M, et al. Endovascular surgery for chronic limb ischaemia. Factors predicting immediate outcome on the basis of a nationwide vascular registry. Ann Chir Gynaecol 2001;90:86-91.
26. Rosenfield K, Schainfeld RS, Isnor JM. Percutaneous revascularization on peripheral arterial disease. Current Prob Cardiol 2001;13:21-28.
27. Lincoff Am, Topol E. Abrupt vessel closure. In: Topol E (ed). Textbook of Interventional Cardiology. WB Saunders: Philadelphia, 1999: pp. 163-187.
28. Best P, Lennon R, Ting H, et al. Even mild renal insufficiency is associated with increased mortality after percutaneous coronary intervention. J Am Coll Cardiol 2001;37:76A.
29. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary interventions in refractory unstable angina; The CAPTURE study. Lancet 1997;349:1429-1435.
30. Ellis SG. Selective coronary angioplasty: Techniques and complications. In: Topol E (ed). Textbook of Interventional Cardiology. WB Saunders: Philadelphia, 1999: pp. 147-162.
31. Meier-Ewert HK, Nesto RW. Targeting the use of glycoprotein IIb/IIIa antagonists-the diabetic patient. Reviews Cardiovasc Med 2002;3:S20-S27.
32. Korn P, Hoenig SJ, Skillman JJ, et al. Is lower extremity revascularization worthwhile in patients with end stage renal disease? Surgery 2000;128:472-479.
33. Panayiotopoulos YP, Tyrell MR, Taylor PR, et al. Results and costs analysis of distal (crural/pedal) arterial revascularization for limb salvage in diabetic and non-diabetic patients. Diabet Med 1997;14:214-220.
34. Robson R. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol 2000;12(Suppl F):33F-36F.
35. Allie DE, Hall P, Virmani A, et al. The Angiomax peripheral procedure registry of vascular events trial (APPROVE): Inhospital and 30-day results. J Invasive Cardiol 2004;16:651-656.
36. Bittl JA, Chaitman B, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: The final reanalysis of the bivalirudin angioplasty study. Am Heart J 2001;142:952-959.
37. Aguirre FV, Gill JB. Increasing benefit, reducing risk: Focusing of hemorrhagic complications in percutaneous coronary intervention. J Invasive Cardiol 2002;14(Suppl B):48B-54B.
38. Shammas NW, Lemke JH, Dippel EJ, et al. In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant. J Invasive Cardiol 2003;15:242-246.
39. Grubbs G. Single center experience with bivalirudin anticoagulation in peripheral vascular interventions: Possible benefits over unfractionated heparin. Poster presented at Cardiovascular Revascularization Therapy Conference. January 26-29, 2003, Washington, D.C.
40. Knopf W. Joseph's Hospital experience: Direct Thrombin Inhibitors in ACS and PCI: The case for bivalirudin replacing unfractionated heparin in PCI. Paper presented at Transcatheter Cardiovascular Therapeutics 14th Annual Scientific Symposium; September 24-28, 2002, Washington D.C.
41. Hasson JE, Acher CW, Wojtowycz, et al. Lower extremity percutaneous transluminal angioplasty: Multifactorial analysis of morbidity and mortality. Surgery 1990;108:748-752.
42. Rosenfield K, Schainfeld RS, Isnor JM. Percutaneous revascularization on peripheral arterial disease. Current Prob Cardiol 2001;13:21-28.
43. Armstrong, DG. MRSA: Where do we go from here? Podiatry Today 2005;18:42-54.
44. Bhatt DL, Marso SP, Lincoff M, et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000;35:922-928.
45. Roffi M, Chew DP, Muherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary syndromes. Circulation 2001;104:2767-2771.
46. Theroux P, Alexander J, Pharand C., et al. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction. Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation 2000;102:2466-2472.
47. Marso SP, Lincoff M, Ellis SG, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus. Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for STENTing Trial) diabetic substudy. Circulation 1999;100:2477-2484.
48. Ansel GM, George BS, Botti CF, et al. Use of glycoprotein IIb/IIIa platelet inhibitors in peripheral vascular interventions. Reviews Cardiovasc Med 2002;3 (Suppl 1):S35-S40.
49. Ross R. Atherosclerosis-an inflammatory disease. N Eng J Med 1999;340:115-126.
50. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: Summary Article. Circulation 2002;106:1893-1900.
51. Allie DE, Hebert CJ, Walker CM, et al. Continuous Tenecteplase infusion combined with peri/postprocedural platelet glycoprotein IIb/IIIa inhibition in peripheral arterial thrombolysis: Initial safety and feasibility experience. J Endovasc Ther 2002;11:427-435.
52. Liebeskind DS, Pollard JR, Hurst RW, et al. Vertebrobasilar thrombolysis with intravenous tirofiban: case report. J Thromb Thrombolysis 2002;13:81-84.
53. Allie DE, Hebert CJ, et al. Simultaneous combination chemical thrombolysis/Rheolytic thrombectomy therapy for acute critical limb ischemia: The Power-Pulse spray technique. Catheter Cardiovasc Interv 2004;63:512-522.